The Department of Health and Human Services
Meeting of the
Secretary's Advisory Committee on Human Research Protections (SACHRP)

Thursday, December 11 & Friday, December 12, 2003
The Sheraton Four Points Hotel
The Franklin Room
1201 K Street, NW
Washington, DC 2005
(202) 289-7600

DRAFT AGENDA

Thursday, December 11, 2003
8:30 a.m. - 8:35 a.m. Welcome, Opening Remarks
Ernest Prentice, Ph.D.
Chairman, SACHRP
8:35 a.m. - 8:45 a.m. Report on Issues
Bernard A. Schwetz, D.V.M., Ph.D.
Acting Director, OHRP
8:45 a.m. - 9:00 a.m. Overview of Charges to Subcommittees
Ernest Prentice, Ph.D.
9:00 a.m. - 10:30 a.m. Subpart D Subcommittee
10:30 a.m. - 10:45 a.m. BREAK
10:45 a.m. - 12:15 p.m. Subpart C Subcommittee
12:15 p.m. - 1:30 p.m. LUNCH
1:30 p.m. - 2:30 p.m. HRPP Accreditation Subcommittee
2:30 p.m. - 3:30 p.m. Public Comment
3:30 p.m. - 3:45 p.m. BREAK
3:45 p.m. - 5:00 p.m. Summary of Day's Activities
Ernest Prentice, Ph.D.


Friday, December 12, 2003
8:30 a.m. - 9:00 a.m. Additional Subcommittee Business
Ernest Prentice, Ph.D.
9:00 a.m. - 10:30 a.m. International Research Issues Panel
International Activities & Challenges
Melody Lin, Ph.D.
Deputy Director, OHRP

Experiences & Challenges in International Research
David Borasky, CIP
Associate Director, Office of International Research Ethics
Family Health International

Infrastructure and Management of Non-Domestic IRBs
Helen McGough, M.A., CIP
Director, Human Subjects Division
University of Washington
10:30 a.m. - 10:45 a.m. BREAK
10:45 a.m. - 12:15 p.m. Adverse Event Reporting Issues - Panel #1
Overview of Regulatory Requirements
Michael Carome, M.D.
Associate Director for Regulatory Affairs, OHRP
Dr. David LePay, M.D., Ph.D.
Senior Advisor on Clinical Science
Office of Science and Health Coordination
Office of the Commisioner
Food and Drug Administration

IRB Perspective
John Zaia, M.D.
Chair, Institutional Review Board
Beckman Research Institute of City of Hope
Patricia Scannell, B.A., CIP
Director, Human Studies Committee
Washington University
12:15 p.m. - 1:15 p.m. LUNCH
1:15 p.m. - 2:45 p.m. Adverse Event Reporting Issues - Panel #2
Drug Industry Perspective
Peter K. Honig, M.D., M.P.H.
Merck Research Laboratories

Device Industry Perspective
Barbara Westrum
Director, Corporate Clinical Affairs
Medtronic

NIH Perspective
Amy Patterson, M.D.
Director, Office of Biotechnology Activities
Office of Science Policy
National Institutes of Health

Role of Data Safety Monitoring Boards
Susan Ellenberg, Ph.D.
Director, Office of Biostatistics and Epidemiology
Center for Biologics Evaluation and Research
Food and Drug Administration
2:45 p.m. - 3:00 p.m. BREAK
3:00 p.m. - 4:00 p.m. Public Comment
4:00 p.m. - 5:00 p.m. Future Business Issues
5:00 p.m. ADJOURN